转甲状腺素蛋白淀粉样变心肌病生物标志物的研究进展  

Biomarkers in Transthyretin Amyloid Cardiomyopathy

作　　者：黎铸 秦俭[1] 罗素新[1] 黄毕 LI Zhu;QIN Jian;LUO Suxin;HUANG Bi(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400042,China)

机构地区：[1]重庆医科大学附属第一医院心血管内科,重庆400042

出　　处：《心血管病学进展》2023年第12期1120-1124,共5页Advances in Cardiovascular Diseases

基　　金：重庆医科大学未来医学青年创新团队支持计划(NO.0184)。

摘　　要：转甲状腺素蛋白淀粉样变心肌病(ATTR-CM)是一种浸润性心肌病,近年来越来越受到重视。由于临床表现缺乏特异性,ATTR-CM的误诊率和漏诊率均较高。随着对该疾病的重视及研究的深入,近年来对ATTR-CM的认识取得了一定的进展。生物标志物对疾病的诊断具有重要价值,虽然目前尚无ATTR-CM特异性的生物标志物,但一些生物标志物已被证实和ATTR-CM相关,对ATTR-CM的辅助诊断具有一定的价值。现综述近年来与ATTR-CM相关的生物标志物的研究进展。Transthyretin amyloid cardiomyopathy(ATTR-CM)is an infiltrative cardiomyopathy,and recently more attention has been paid on it.Due to the lack of specificity of clinical manifestations,there remains substantial delay between initial symptoms and diagnosis.The understanding of ATTR-CM has made some progress with the attention to the disease in recent years.Biomarkers are of great value in the diagnosis of diseases.Although there is lack of specific biomarker for ATTR-CM at present,some biomarkers have been confirmed to be related to ATTR-CM and have certain value in the auxiliary diagnosis of ATTR-CM.This article reviews the recent progress of biomarkers related to ATTR-CM.

关 键 词：转甲状腺素蛋白淀粉样变心肌病 生物标志物 视黄醇结合蛋白 非天然甲状腺素 多肽探针 神经丝轻链 

分 类 号：R542.2[医药卫生—心血管疾病]